Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile KDR Q472H
Therapy Dabrafenib + Lenvatinib + Trametinib
Indication/Tumor Type melanoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KDR Q472H melanoma sensitive Dabrafenib + Lenvatinib + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Lenvima (lenvatinib) treatment to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) decreased proliferation compared to the combination alone in melanoma cell lines expressing KDR Q472H in culture (PMID: 38201446). 38201446
PubMed Id Reference Title Details
(38201446) Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. Full reference...